R&D Briefing Session

2025.12.11

• IR News

We held an R&D briefing for analysts and institutional investors on December 4.
In this session, we provided an overview of the strategic priorities set forth in our Second Mid-Term Management Plan announced in May 2025,
namely:“Creation of new value through KAMPOmics®, market development of evidence-based “three preventive measures for pre-symptomatic diseases,”and the challenge of globalizing Kampo medicine”

Please refer to the materials related to the R&D briefing below:R&D Briefing Materials